Luisa M Solis Soto, M.D.
Department of Translational Molecular Pathology, Division of Pathology-Lab Medicine Div
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Translational Molecular Pathology, Division of Pathology-Lab Medicine Div, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
2003 | University of San Francisco Xavier, Chuquisaca Sucre, BO, MD |
Postgraduate Training
2007-2011 | Research Fellowship, Molecular Pathology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas |
2004-2007 | Clinical Residency, Anatomic Pathology, Catholic University of Chile, Santiago |
Board Certifications
2011 | Anatomic Pathology, Bolivia |
2007 | Anatomic Pathology, Chile |
Experience & Service
Academic Appointments
Assistant Professor, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2018 - 2023
Administrative Appointments/Responsibilities
Co-Director, TMP-IL Moonshot Platform, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Director of the Immunohistochemistry and Digital Pathology Laboratory, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Other Appointments/Responsibilities
Sr. Research Scientist, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2018
Sr. Research Scientist, ECOG-ACRIN Central Biorepository and Pathology Facilities, Immunohistochemistry and Digital Pathology Lab, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2017
Pathologist, Hospital Jaime Mendoza, Caja Nacional de Salud, Sucre, 2013 - 2015
Pathologist, Institute of Anatomic Pathology-Hospital Sta. Barbara, University of San Francisco Xavier de Chuquisaca, Sucre, 2012 - 2015
Pathologist, Private Laboratory of Pathology “ONCOS”, Santa Cruz, 2011 - 2012
Institutional Committee Activities
Member, Research Enablement, Activities and Conduct (REACT) committee, 2024 - Present
Senator, Faculty Senate, 2024 - 2027
Member, MD Anderson Data and Biospecimen Access Committee (DBAC), 2022 - Present
Member, Division of Pathology and Laboratory Medicine Diversity, Equity and Inclusion (DEI) Committee, 2021 - 2023
Member, Digital Pathology Request for Proposal (RFP) Committee, 2021 - 2024
Member, Lung Tissue and Data Committee (TTDC), 2021 - Present
Member, Clinical Genomics and Biomarker Council (CGC), 2021 - Present
Member, Computational Pathology Research Program Committee, 2020 - Present
Honors & Awards
Travel award -9th Annual Targeted Therapies of the Treatment of Lung Cancer – The Fairmont Miramar Hotel, Santa Monica, CA | |
DPLM Early Career Faculty and Instructor Research Award, The Department of Pathology and Laboratory Medicine | |
2020 ITERT Outstanding Mentorship Awardees: Peer Mentors, The University of Texas MD Anderson Cancer Center |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Serrano AG, Rocha P, Freitas Lima C, Stewart A, Zhang B, Diao L, Fujimoto J, Cardnell RJ, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Concannon KF, Halperin DM, Bogdan C, Sircar K, Zhang M, Cargill K, Wang Q, Aparicio A, Lazar A, Hernandez S, Estrella J, Ramalingam P, El-Naggar A, Kalhor N, Gay CM, Byers LA, Solis Soto LM. Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. NPJ Precis Oncol 8(1):268, 2024. PMID: 39558076.
- Thomas-Jardin S, Suresh S, Arce A, Novaresi N, Stein E, Thomas L, Lewis C, Ahn C, Evers BM, Salvatierra ME, Lui W, Khan K, Solis Soto LM, Wistuba I, Minna JD, O'Donnell KA. Coordinated translational control of multiple immune checkpoints by the integrated stress response pathway in lung cancer. bioRxiv None(None):None, 2024. PMID: 39554171.
- Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10):None, 2024. PMID: 39448200.
- How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med None(None):None, 2024. PMID: 39151421.
- Araujo HA, Pechuan-Jorge X, Zhou T, Do MT, Hu X, Rojas Alvarez FR, Salvatierra ME, Ibarguen HP, Lee R, Raghulan R, Shah H, Moreno Ayala MA, Chen K, Tovbis Shifrin N, Wu S, Solis Soto LM, Negrao MV, Gibbons DL, Hong DS, Roth JA, Heymach JV, Zhang J, Jiang J, Singh M, Smith JAM, Quintana E, Skoulidis F. Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC. Cancer Discov None(None):None, 2024. PMID: 38975897.
- He S, Gubin MM, Rafei H, Basar R, Dede M, Jiang X, Liang Q, Tan Y, Kim K, Gillison ML, Rezvani K, Peng W, Haymaker C, Hernandez S, Solis LM, Mohanty V, Chen K. Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles. iScience 27(6):110096, 2024. PMID: 38957791.
- Acharya S, Basar R, Daher M, Rafei H, Li P, Uprety N, Ensley E, Shanley M, Kumar B, Banerjee PP, Melo Garcia L, Lin P, Mohanty V, Kim KH, Jiang X, Pan Y, Li Y, Liu B, Nunez Cortes AK, Zhang C, Fathi M, Rezvan A, Montalvo MJ, Cha SL, Reyes-Silva F, Shrestha R, Guo X, Kundu K, Biederstadt A, Muniz-Feliciano L, Deyter GM, Kaplan M, Jiang XR, Liu E, Jain A, Roszik J, Fowlkes NW, Solis Soto LM, Raso MG, Khoury JD, Lin P, Vega F, Varadarajan N, Chen K, Marin D, Shpall EJ, Rezvani K. CD28 costimulation augments CAR signaling in NK cells via the LCK/CD3Z/ZAP70 signaling axis. Cancer Discov None(None):None, 2024. PMID: 38900051.
- Seth S, Chen R, Liu Y, Fujimoto J, Hong L, Reuben A, Varghese S, Behrens C, McDowell T, Soto LS, Haymaker C, Weissferdt A, Kalhor N, Wu J, Le X, Vokes NI, Cheng C, Heymach JV, Gibbons DL, Futreal PA, Wistuba II, Kadara H, Zhang J, Moran C, Zhang J. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innov 3(3):e112, 2024. PMID: 38947760.
- Hu X, Zhu B, Vokes N, Fujimoto J, Rojas Alvarez FR, Heeke S, Moreira AL, Solis LM, Haymaker C, Velcheti V, Sterman DH, Pass HI, Cheng C, Lee JJ, Zhang J, Wei Z, Wu J, Le X, Ostrin E, Toumazis I, Gibbons D, Su D, Fukuoka J, Antonoff MB, Gerber DE, Li C, Kadara H, Wang L, Davis M, Heymach JV, Hannash S, Wistuba I, Dubinett S, Alexandrov L, Lippman S, Spira A, Futreal AP, Reuben A, Zhang J. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion. Res Sq None(None):None, 2024. PMID: 38798564.
- He S, Gubin MM, Rafei H, Basar R, Dede M, Jiang X, Liang Q, Tan Y, Kim K, Gillison ML, Rezvani K, Peng W, Haymaker C, Hernandez S, Solis LM, Mohanty V, Chen K. Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles. bioRxiv None(None):None, 2024. PMID: 38798470.
- Khanduri I, Maki H, Verma A, Katkhuda R, Anandappa G, Pandurengan R, Zhang S, Mejia A, Tong Z, Solis Soto LM, Jadhav A, Wistuba II, Menter D, Kopetz S, Parra ER, Vauthey JN, Maru DM. New insights into macrophage polarization and its prognostic role in patients with colorectal cancer liver metastasis. BJC Rep 2(1):37, 2024. PMID: 39516662.
- Liang Q, Soto LS, Haymaker C, Chen K. Interpretable Spatial Gradient Analysis for Spatial Transcriptomics Data. bioRxiv None(None):None, 2024. PMID: 38562886.
- Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer 130(6):876-885, 2024. PMID: 37985359.
- Treekitkarnmongkol W, Solis LM, Sankaran D, Gagea M, Singh PK, Mistry R, Nguyen T, Kai K, Liu J, Sasai K, Jitsumori Y, Liu J, Nagao N, Stossi F, Mancini MA, Wistuba II, Thompson AM, Lee JM, Cadinanos J, Wong KK, Abbott CM, Sahin AA, Liu S, Katayama H, Sen S. eEF1A2 promotes PTEN-GSK3beta-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Sci Signal 17(826):eadh4475, 2024. PMID: 38442201.
- Han G, Sinjab A, Rahal Z, Lynch AM, Treekitkarnmongkol W, Liu Y, Serrano AG, Feng J, Liang K, Khan K, Lu W, Hernandez SD, Liu Y, Cao X, Dai E, Pei G, Hu J, Abaya C, Gomez-Bolanos LI, Peng F, Chen M, Parra ER, Cascone T, Sepesi B, Moghaddam SJ, Scheet P, Negrao MV, Heymach JV, Li M, Dubinett SM, Stevenson CS, Spira AE, Fujimoto J, Solis LM, Wistuba II, Chen J, Wang L, Kadara H. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature 627(8004):656-663, 2024. PMID: 38418883.
- Marques-Piubelli ML, Kumar B, Basar R, Panowski S, Srinivasan S, Norwood K, Prashad S, Szenes V, Balakumaran A, Arandhya A, Lu W, Khan K, Duenas D, McAllen S, Gomez JA, Burks JK, Acharyal S, Borthakur G, Wang WL, Wang W, Wang S, Solis LM, Marin D, Rezvani K, Daher M, Vega F. Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents. Virchows Arch 485(5):937-941, 2024. PMID: 38388965.
- Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets. JTO Clin Res Rep 5(2):100623, 2024. PMID: 38357092.
- Wen Z, Luo D, Wang S, Rong R, Evers BM, Jia L, Fang Y, Daoud EV, Yang S, Gu Z, Arner EN, Lewis CM, Solis Soto LM, Fujimoto J, Behrens C, Wistuba II, Yang DM, Brekken RA, O'Donnell KA, Xie Y, Xiao G. Deep Learning-Based H-Score Quantification of Immunohistochemistry-Stained Images. Mod Pathol 37(2):100398, 2024. PMID: 38043788.
- Solorzano JL, Menendez V, Parra E, Solis L, Salazar R, Garcia-Cosio M, Climent F, Fernandez S, Diaz E, Francisco-Cruz A, Khoury J, Jiang M, Tamegnon A, Montalban C, Melero I, Wistuba I, De Andrea C, F Garcia J. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma. Oncoimmunology 13(1):2388304, 2024. PMID: 39135889.
- Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JM. Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. J Clin Invest 133(24), 2023. PMID: 37874652.
- Chen P, Rojas FR, Hu X, Serrano A, Zhu B, Chen H, Hong L, Bandyoyadhyay R, Aminu M, Kalhor N, Lee JJ, El Hussein S, Khoury JD, Pass HI, Moreira AL, Velcheti V, Sterman DH, Fukuoka J, Tabata K, Su D, Ying L, Gibbons DL, Heymach JV, Wistuba II, Fujimoto J, Solis Soto LM, Zhang J, Wu J. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma. Mod Pathol 36(12):100326, 2023. PMID: 37678674.
- Khanduri I, Maki H, Verma A, Katkhuda R, Anandappa G, Pandurengan R, Zhang S, Mejia A, Tong Z, Soto LMS, Jadhav A, Wistuba II, Kopetz S, Parra ER, Vauthey JN, Maru DM. New Insights into Macrophage Polarization and its Prognostic Role in Patients with Colorectal Cancer Liver Metastasis. Res Sq None(None):None, 2023. PMID: 37886575.
- Diao S, Chen P, Showkatian E, Bandyopadhyay R, Rojas FR, Zhu B, Hong L, Aminu M, Saad MB, Salehjahromi M, Muneer A, Sujit SJ, Behrens C, Gibbons DL, Heymach JV, Kalhor N, Wistuba II, Solis Soto LM, Zhang J, Qin W, Wu J. Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis. Cancers (Basel) 15(19), 2023. PMID: 37835518.
- Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JM. Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. bioRxiv None(None):None, 2023. PMID: 37808840.
- Xiao GY, Tan X, Rodriguez BL, Gibbons DL, Wang S, Wu C, Liu X, Yu J, Vasquez ME, Tran HT, Xu J, Russell WK, Haymaker C, Lee Y, Zhang J, Solis L, Wistuba II, Kurie JM. EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer. Proc Natl Acad Sci U S A 120(28):e2220276120, 2023. PMID: 37406091.
- Marques-Piubelli ML, Kim DH, Medeiros LJ, Lu W, Khan K, Gomez-Bolanos LI, Rodriguez S, Parra ER, Ok CY, Aradhya A, Solis LM, Nieto YL, Steiner R, Ahmed S, Vega F. CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy. Histopathology 83(1):143-148, 2023. e-Pub 2023. PMID: 36994939.
- Marques-Piubelli ML, Seervai RNH, Mudaliar KM, Ma W, Milton DR, Wang J, Muhlbauer A, Parra ER, Solis LM, Nagarajan P, Speiser J, Hudgens C, Cho WC, Aung PP, Patel A, Pacha O, Nelson KC, Tetzlaff MT, Amaria RN, Torres-Cabala CA, Prieto VG, Wistuba II, Curry JL. Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T(H) 1 T-cells. J Cutan Pathol 50(7):661-673, 2023. PMID: 37150813.
- Sanchez JI, Parra ER, Jiao J, Solis Soto LM, Ledesma DA, Saldarriaga OA, Stevenson HL, Beretta L. Cellular and Molecular Mechanisms of Liver Fibrosis in Patients with NAFLD. Cancers (Basel) 15(11), 2023. e-Pub 2023. PMID: 37296834.
- Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun 14(1):2684, 2023. PMID: 37164948.
- Parra ER, Zhang J, Jiang M, Tamegnon A, Pandurengan RK, Behrens C, Solis L, Haymaker C, Heymach JV, Moran C, Lee JJ, Gibbons D, Wistuba II. Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer. Nat Commun 14(1):2364, 2023. PMID: 37185575.
- Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol 12(1):32, 2023. e-Pub 2023. PMID: 36941707.
- Hernandez S, Das P, Holliday EB, Shen L, Lu W, Johnson B, Messick CA, Taniguchi CM, Skibber J, Ludmir EB, You YN, Smith GL, Bednarski B, Kostousov L, Koay EJ, Minsky BD, Tillman M, Portier S, Eng C, Koong AC, Chang GJ, Foo WC, Wang J, Soto LS, Morris VK. Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer. Cancers (Basel) 15(6), 2023. e-Pub 2023. PMID: 36980587.
- Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
- Jiao J, Sanchez JI, Saldarriaga OA, Solis LM, Tweardy DJ, Maru DM, Stevenson HL, Beretta L. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease. JHEP Rep 5(2):100628, 2023. e-Pub 2022. PMID: 36687470.
- Sun B, Laberiano-Fernández C, Salazar-Alejo R, Zhang J, Solorzano Rendon JL, Lee J, Solis Soto LM, Wistuba II, Parra ER. Impact of Region-of-Interest Size on Immune Profiling Using Multiplex Immunofluorescence Tyramide Signal Amplification for Paraffin-Embedded Tumor Tissues. Pathobiology 90(1):1-12, 2023. e-Pub 2022. PMID: 35609532.
- Gulhati P, Schalck A, Jiang S, Shang X, Wu CJ, Hou P, Ruiz SH, Soto LS, Parra E, Ying H, Han J, Dey P, Li J, Deng P, Sei E, Maeda DY, Zebala JA, Spring DJ, Kim M, Wang H, Maitra A, Moore D, Clise-Dwyer K, Wang YA, Navin NE, DePinho RA. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat Cancer 4(1):62-80, 2023. e-Pub 2022. PMID: 36585453.
- Francisco-Cruz A, Rocha P, Reuben A, Krishnan SN, Das P, Chen R, Quek K, Li J, Parra ER, Solis LM, Barua S, Jiang M, Lazcano R, Chow CW, Behrens C, Gumb C, Little L, Fukuoka J, Kalhor N, Weissferdt A, Kadara H, Heymach JV, Swisher S, Sepesi B, Rao A, Moran C, Zhang J, Lee JJ, Fujimoto J, Futreal PA, Wistuba II, Peterson CB, Zhang J. Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer. Mod Pathol 36(1):100028, 2023. PMID: 36788067.
- Rodriguez BL, Chen L, Li Y, Miao S, Peng DH, Fradette JJ, Diao L, Konen JM, Alvarez FRR, Solis LM, Yi X, Padhye A, Gibson LA, Ochieng JK, Zhou X, Wang J, Gibbons DL. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance. Front Immunol 14:1161869, 2023. PMID: 37449205.
- Bowen CM, Deng N, Reyes-Uribe L, Parra ER, Rocha P, Solis LM, Wistuba II, Sepeda VO, Vornik L, Perloff M, Szabo E, Umar A, Sinha KM, Brown PH, Vilar E. Naproxen chemoprevention induces proliferation of cytotoxic lymphocytes in Lynch Syndrome colorectal mucosa. Front Immunol 14:1162669, 2023. PMID: 37207208.
- Le UQ, Chen N, Balasenthil S, Lurie E, Yang F, Liu S, Rubin L, Solis Soto LM, Raso MG, Batra H, Sahin AA, Wistuba II, Killary AM. Tumor suppressor DEAR1 regulates mammary epithelial cell fate and predicts early onset and metastasis in triple negative breast cancer. Sci Rep 12(1):19504, 2022. e-Pub 2022. PMID: 36376460.
- Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, Hernandez SD, Dai E, Cao X, Hu J, Dang M, Wang R, Chu Y, Song X, Zhang J, Parra ER, Wargo JA, Swisher SG, Cascone T, Sepesi B, Futreal AP, Li M, Dubinett SM, Fujimoto J, Solis Soto LM, Wistuba II, Stevenson CS, Spira A, Shalapour S, Kadara H, Wang L. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov 12(11):2626-2645, 2022. PMID: 36098652.
- Akhave N, Zhang J, Bayley E, Frank M, Chiou SH, Behrens C, Chen R, Hu X, Parra ER, Lee WC, Swisher S, Solis L, Weissferdt A, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Heymach JV, Lee JJ, Wistuba II, Andrew Futreal P, Zhang J, Fujimoto J, Reuben A. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer 172:19-28, 2022. e-Pub 2022. PMID: 35973335.
- Bajaj R, Rodriguez BL, Russell WK, Warner AN, Diao L, Wang J, Raso MG, Lu W, Khan K, Solis LS, Batra H, Tang X, Fradette JF, Kundu ST, Gibbons DL. Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis. Cell Rep 40(13):111429, 2022. PMID: 36170810.
- Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression. Blood Cancer Discov 3(5):428-443, 2022. PMID: 35687817.
- Romain G, Strati P, Rezvan A, Fathi M, Bandey IN, Adolacion JRT, Heeke D, Liadi I, Marques-Piubelli ML, Solis LM, Mahendra A, Vega F, Cooper LJ, Singh H, Mattie M, Bot A, Neelapu SS, Varadarajan N. Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses. J Clin Invest 132(17), 2022. PMID: 35881486.
- Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol 23(9):1156-1166, 2022. e-Pub 2022. PMID: 35934010.
- Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat Commun 13(1):4640, 2022. e-Pub 2022. PMID: 35941179.
- Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. Br J Cancer 127(3):569-576, 2022. e-Pub 2022. PMID: 35440668.
- Marques-Piubelli ML, Sagert J, Pham MT, Will M, Henderson D, Tipton K, Iyer S, Lu W, Khan KB, Hamana L, Chapman JR, Thakral B, Xu J, Miranda RN, Jennings K, Solis LM, Vega F. CD70 is a potential target biomarker in peripheral T-cell lymphomas. Histopathology 81(2):272-275, 2022. e-Pub 2022. PMID: 35474464.
- Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer 10(8), 2022. PMID: 36007963.
- Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat Commun 13(1):4327, 2022. e-Pub 2022. PMID: 35882862.
- Hassane M, Rahal Z, Karaoghlanian N, Zhang J, Sinjab A, Wong JW, Lu W, Scheet P, Lee JJ, Raso MG, Solis LM, Fujimoto J, Chami H, Shihadeh AL, Kadara H. Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung. Cancer Prev Res (Phila) 15(7):423-434, 2022. PMID: 35468191.
- Soundararajan R, Viscuse P, Pilie P, Liu J, Logotheti S, Laberiano Fernández C, Lorenzini D, Hoang A, Lu W, Soto LMS, Wistuba II, Xu M, Song X, Shepherd PDA, Navone NM, Tidwell RSS, Lozano G, Logothetis C, Zhang J, Long JP, Estecio MR, Tzelepi V, Aparicio AM. Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components. Cancers (Basel) 14(13), 2022. e-Pub 2022. PMID: 35805010.
- Marques-Piubelli ML, Parra ER, Feng L, Soto LS, Gallardo M, Gouni S, Samaniego F, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Fowler NH, Flowers CR, Wistuba II, Nastoupil LJ, Vega F, Strati P. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv 6(11):3286-3293, 2022. PMID: 35359004.
- Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol 8(6):904-909, 2022. PMID: 35389428.
- Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Bota-Rabassedas N, Sanchez-Espiridon B, Yoshimura K, Behrens C, Lu W, Tang X, Pataer A, Parra ER, Haymaker C, Fujimoto J, Swisher SG, Heymach JV, Gibbons DL, Lee JJ, Sepesi B, Cascone T, Solis LM, Provencio M, Wistuba II, Kadara H. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clin Cancer Res 28(11):2461-2473, 2022. PMID: 35394499.
- Fahrmann JF, Tanaka I, Irajizad E, Mao X, Dennison JB, Murage E, Casabar J, Mayo J, Peng Q, Celiktas M, Vykoukal JV, Park S, Taguchi A, Delgado O, Tripathi SC, Katayama H, Soto LMS, Rodriguez-Canales J, Behrens C, Wistuba I, Hanash S, Ostrin EJ. Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma. Cancers (Basel) 14(10), 2022. e-Pub 2022. PMID: 35626147.
- Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40(5):509-523.e6, 2022. e-Pub 2022. PMID: 35537412.
- Hernandez S, Parra ER, Uraoka N, Tang X, Shen Y, Qiao W, Jiang M, Zhang S, Mino B, Lu W, Pandurengan R, Haymaker C, Affolter K, Scaife CL, Yip-Schneider M, Schmidt CM, Firpo MA, Mulvihill SJ, Koay EJ, Wang H, Wistuba II, Maitra A, Solis LM, Sen S. Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception. Clin Cancer Res 28(9):1938-1947, 2022. PMID: 35491652.
- Sun X, Zhai J, Sun B, Parra ER, Jiang M, Ma W, Wang J, Kang AM, Kannan K, Pandurengan R, Zhang S, Solis LM, Haymaker CL, Raso MG, Mendoza Perez J, Sahin AA, Wistuba II, Yam C, Litton JK, Yang F. Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Mod Pathol 35(5):601-608, 2022. e-Pub 2021. PMID: 34839351.
- Kundu ST, Rodriguez BL, Gibson LA, Warner AN, Perez MG, Bajaj R, Fradette JJ, Class CA, Solis LM, Rojas Alvarez FR, Wistuba II, Diao L, Chen F, Sachdeva M, Wang J, Kirsch DG, Creighton CJ, Gibbons DL. The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response. Genes Dev 36(9-10):582-600, 2022. e-Pub 2022. PMID: 35654454.
- Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
- Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, Park H, Zhang A, Dong C, Ye J, Rayford A, Peyton M, Li X, Avila K, Cao X, Hu S, Alam MM, Akbay EA, Solis LM, Behrens C, Hernandez-Ruiz S, Lu W, Wistuba I, Heymach JV, Chisamore M, Micklem D, Gabra H, Gausdal G, Lorens JB, Li B, Fu YX, Minna JD, Brekken RA. AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. Cell Rep Med 3(3):100554, 2022. e-Pub 2022. PMID: 35492873.
- Wang J, Wang WL, Sun H, Huo L, Wu Y, Chen H, Gan Q, Meis JM, Maloney N, Lazar AJ, Yoon EC, Albarracin CT, Krishnamurthy S, Middleton LP, Resetkova E, Yu W, Tan D, Lu W, Solis Soto LM, Wang S, Wistuba II, Parwani AV, Prieto VG, Sahin AA, Li Z, Ding Q. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol 121:73-80, 2022. e-Pub 2022. PMID: 35063444.
- Tanaka I, Dayde D, Tai MC, Mori H, Solis LM, Tripathi SC, Fahrmann JF, Unver N, Parhy G, Jain R, Parra ER, Murakami Y, Aguilar-Bonavides C, Mino B, Celiktas M, Dhillon D, Casabar JP, Nakatochi M, Stingo F, Baladandayuthapani V, Wang H, Katayama H, Dennison JB, Lorenzi PL, Do KA, Fujimoto J, Behrens C, Ostrin EJ, Rodriguez-Canales J, Hase T, Fukui T, Kajino T, Kato S, Yatabe Y, Hosoda W, Kawaguchi K, Yokoi K, Chen-Yoshikawa TF, Hasegawa Y, Gazdar AF, Wistuba II, Hanash S, Taguchi A. SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas. J Natl Cancer Inst 114(2):290-301, 2022. PMID: 34524427.
- Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology 75(2):297-308, 2022. e-Pub 2021. PMID: 34510503.
- Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Ann Oncol 33(1):42-56, 2022. e-Pub 2021. PMID: 34653632.
- Hong DS, Butler MO, Pachynski RK, Sullivan R, Kebriaei P, Boross-Harmer S, Ghobadi A, Frigault MJ, Dumbrava EE, Sauer A, Brophy F, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou DG, Wang R, Solis LM, Duose DY, Sanderson JP, Gerry AB, Marks D, Bai J, Norry E, Fracasso PM. Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol 12:818679, 2022. e-Pub 2022. PMID: 35372008.
- Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol 12:1008484, 2022. e-Pub 2022. PMID: 36313661.
- Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
- Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
- Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discov 11(10):2506-2523, 2021. e-Pub 2021. PMID: 33972311.
- Marques-Piubelli ML, Solis LM, Parra ER, Castillo LM, Gouni S, Nair R, Chihara D, Konopleva M, Wistuba II, Iyer SP, Vega F, Strati P. BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified. Blood Cancer J 11(9):153, 2021. e-Pub 2021. PMID: 34531377.
- Padhye A, Konen JM, Rodriguez BL, Fradette JJ, Ochieng JK, Diao L, Wang J, Lu W, Solis LS, Batra H, Raso MG, Peoples MD, Minelli R, Carugo A, Bristow CA, Gibbons DL. Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer. JCI Insight 6(17), 2021. e-Pub 2021. PMID: 34309585.
- Cascone T, Weissferdt A, Godoy MCB, William WN, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 12(1):5045, 2021. e-Pub 2021. PMID: 34413300.
- Zhao J, Soto LMS, Wang H, Katz MH, Prakash LR, Kim M, Tzeng CD, Lee JE, Wolff RA, Huang Y, Wistuba II, Maitra A, Wang H. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Pancreatology 21(5):942-949, 2021. e-Pub 2021. PMID: 33832821.
- Joseph R, Soundararajan R, Vasaikar S, Yang F, Allton KL, Tian L, den Hollander P, Isgandarova S, Haemmerle M, Mino B, Zhou T, Shin C, Martinez-Paniagua M, Sahin AA, Rodriguez-Canales J, Gelovani J, Chang JT, Acharya G, Sood AK, Wistuba II, Gibbons DL, Solis LM, Barton MC, Varadarajan N, Rosen JM, Zhang XH, Mani SA. CD8+ T cells inhibit metastasis and CXCL4 regulates its function. Br J Cancer 125(2):176-189, 2021. e-Pub 2021. PMID: 33795809.
- Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 70(7):1977-1978, 2021. e-Pub 2021. PMID: 33686493.
- Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 70(7):1965-1976, 2021. e-Pub 2021. PMID: 33416944.
- Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal PA, Kee B, Menter D, Solis LM, Tzeng CD, Parseghian CM, Raghav K, Morris VK, Chang CC, Jenq RR, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
- Dejima H, Hu X, Chen R, Zhang J, Fujimoto J, Parra ER, Haymaker C, Hubert SM, Duose D, Solis LM, Su D, Fukuoka J, Tabata K, Pham HHN, Mcgranahan N, Zhang B, Ye J, Ying L, Little L, Gumbs C, Chow CW, Estecio MR, Godoy MCB, Antonoff MB, Sepesi B, Pass HI, Behrens C, Zhang J, Vaporciyan AA, Heymach JV, Scheet P, Lee JJ, Wu J, Futreal PA, Reuben A, Kadara H, Wistuba II, Zhang J. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun 12(1):2722, 2021. e-Pub 2021. PMID: 33976164.
- Marques-Piubelli ML, Schlette EJ, Khoury JD, Furqan F, Vega F, Soto LMS, Wistuba II, Wierda WG, Konopleva M, Ferrajoli A, Strati P. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leuk Lymphoma 62(5):1129-1135, 2021. e-Pub 2020. PMID: 33327833.
- Behrens C, Rocha P, Parra ER, Feng L, Rodriguez-Canales J, Solis LM, Mino B, Zhang J, Gibbons DL, Sepesi B, Rice D, Heymach JV, Moran C, Creighton CJ, Lee JJ, Kadara H, Wistuba II. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clin Lung Cancer 22(3):e415-e424, 2021. e-Pub 2020. PMID: 32763065.
- Bota-Rabassedas N, Banerjee P, Niu Y, Cao W, Luo J, Xi Y, Tan X, Sheng K, Ahn YH, Lee S, Parra ER, Rodriguez-Canales J, Albritton J, Weiger M, Liu X, Guo HF, Yu J, Rodriguez BL, Firestone JJA, Mino B, Creighton CJ, Solis LM, Villalobos P, Raso MG, Sazer DW, Gibbons DL, Russell WK, Longmore GD, Wistuba II, Wang J, Chapman HA, Miller JS, Zong C, Kurie JM. Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. Cell Rep 35(3):109009, 2021. PMID: 33882319.
- Parra ER, Ferrufino-Schmidt MC, Tamegnon A, Zhang J, Solis L, Jiang M, Ibarguen H, Haymaker C, Lee JJ, Bernatchez C, Wistuba II. Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. Sci Rep 11(1):8511, 2021. e-Pub 2021. PMID: 33875760.
- Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol 16(4):583-600, 2021. e-Pub 2020. PMID: 33388477.
- Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34(4):710-719, 2021. e-Pub 2020. PMID: 33011748.
- Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel) 13(6):1-13, 2021. e-Pub 2021. PMID: 33809063.
- Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39(3):346-360.e7, 2021. e-Pub 2021. PMID: 33482121.
- Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
- Reyes-Uribe L, Wu W, Gelincik O, Bommi PV, Francisco-Cruz A, Solis LM, Lynch PM, Lim R, Stoffel EM, Kanth P, Samadder NJ, Mork ME, Taggart MW, Milne GL, Marnett LJ, Vornik L, Liu DD, Revuelta M, Chang K, You YN, Kopelovich L, Wistuba II, Lee JJ, Sei S, Shoemaker RH, Szabo E, Richmond E, Umar A, Perloff M, Brown PH, Lipkin SM, Vilar E. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut 70(3):555-566, 2021. e-Pub 2020. PMID: 32641470.
- Treekitkarnmongkol W, Hassane M, Sinjab A, Chang K, Hara K, Rahal Z, Zhang J, Lu W, Sivakumar S, McDowell TL, Kantrowitz J, Zhou J, Lang W, Xu L, Ochieng JK, Nunomura-Nakamura S, Deng S, Behrens C, Raso MG, Fukuoka J, Reuben A, Ostrin EJ, Parra E, Solis LM, Spira AE, McAllister F, Cascone T, Wistuba II, Moghaddam SJ, Scheet PA, Fujimoto J, Kadara H. Augmented Lipocalin-2 is Associated with COPD and Counteracts Lung Adenocarcinoma Development. Am J Respir Crit Care Med 203(1):90-101, 2021. e-Pub 2020. PMID: 32730093.
- Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, Wei Y, Chapman HA, Yamauchi M, Behrens C, Raso G, Soto LMS, Cuentes ERP, Wistuba II, Kurie JM, Gibbons DL. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun 11(1):4520, 2020. e-Pub 2020. PMID: 32908154.
- Lyapichev KA, You MJ, Vega F, Solis LM, Medeiros LJ. Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging. Virchows Arch 477(3):437-444, 2020. e-Pub 2020. PMID: 32152665.
- Carroll MR, Ramalingam P, Salvo G, Fujimoto J, Solis Soto LM, Phoolcharoen N, Hillman RT, Cardnell R, Byers L, Frumovitz M. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. Int J Gynecol Cancer 30(9):1303-1307, 2020. e-Pub 2020. PMID: 32727929.
- Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Wistuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. J Thorac Oncol 15(5):777-791, 2020. e-Pub 2020. PMID: 32068166.
- Kasiri S, Chen B, Wilson AN, Reczek A, Mazambani S, Gadhvi J, Noel E, Marriam U, Mino B, Lu W, Girard L, Solis LM, Luby-Phelps K, Bishop J, Kim JW, Kim J. Stromal Hedgehog pathway activation by IHH suppresses lung adenocarcinoma growth and metastasis by limiting reactive oxygen species. Oncogene 39(16):3258-3275, 2020. e-Pub 2020. PMID: 32108165.
- Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood 135(7):510-513, 2020. PMID: 31895947.
- Park JS, Burckhardt CJ, Lazcano R, Solis LM, Isogai T, Li L, Chen CS, Gao B, Minna JD, Bachoo R, DeBerardinis RJ, Danuser G. Mechanical regulation of glycolysis via cytoskeleton architecture. Nature 578(7796):621-626, 2020. e-Pub 2020. PMID: 32051585.
- Tan X, Banerjee P, Pham EA, Rutaganira FUN, Basu K, Bota-Rabassedas N, Guo HF, Grzeskowiak CL, Liu X, Yu J, Shi L, Peng DH, Rodriguez BL, Zhang J, Zheng V, Duose DY, Solis LM, Mino B, Raso MG, Behrens C, Wistuba II, Scott KL, Smith M, Nguyen K, Lam G, Choong I, Mazumdar A, Hill JL, Gibbons DL, Brown PH, Russell WK, Shokat K, Creighton CJ, Glenn JS, Kurie JM. PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma. Sci Transl Med 12(527), 2020. PMID: 31969487.
- Veeranki OL, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, Kim TB, Wang J, Lang W, Mino B, Solis L, Kingsley C, Norton W, Tailor R, Wu JY, Krishnan S, Lin SH, Blum M, Hofstetter W, Ajani J, Kopetz S, Maru D. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech. e-Pub 2019. PMID: 31732509.
- Zheng L, Chen Z, Kawakami M, Chen Y, Roszik J, Mustachio LM, Kurie JM, Villalobos P, Lu W, Behrens C, Mino B, Solis LM, Silvester J, Thu KL, Cescon DW, Rodriguez-Canales J, Wistuba II, Mak TW, Liu X, Dmitrovsky E. Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy. Mol Cancer Ther 18(10):1775-1786, 2019. e-Pub 2019. PMID: 31358662.
- Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra ER, Mino B, Abraham R, Ikeda N, Vaporcyan A, Gibbons D, Zhang J, Lang FF, Luthra R, Lee JJ, Moran C, Huse JT, Kadara H, Wistuba II. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol 30(9):1521-1530, 2019. PMID: 31282941.
- Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol 11:1758835919864850, 2019. e-Pub 2019. PMID: 31384313.
- Alvarez C, Aravena A, Tapia T, Rozenblum E, Solís L, Corvalán A, Camus M, Alvarez M, Munroe D, Maass A, Carvallo P. Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival. BMC Cancer 16:219, 2016. e-Pub 2016. PMID: 26979459.
- Zhu X, Xu Y, Solis LM, Tao W, Wang L, Behrens C, Xu X, Zhao L, Liu D, Wu J, Zhang N, Wistuba II, Farokhzad OC, Zetter BR, Shi J. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci U S A 112(25):7779-84, 2015. e-Pub 2015. PMID: 26056316.
- Zenali MJ, Weissferdt A, Solis LM, Ali S, Tang X, Mehran RJ, Wistuba II, Moran CA, Kalhor N. An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung. Hum Pathol 46(6):836-42, 2015. e-Pub 2015. PMID: 25776025.
- Quintás-Cardama A, Post SM, Solis LM, Xiong S, Yang P, Chen N, Wistuba II, Killary AM, Lozano G. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol 234(1):108-19, 2014. e-Pub 2014. PMID: 24890125.
- Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee HY. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer 15(3):213-21, 2014. e-Pub 2014. PMID: 24485233.
- Gold KA, Kim ES, Liu DD, Yuan P, Behrens C, Solis LM, Kadara H, Rice DC, Wistuba II, Swisher SG, Hofstetter WL, Lee JJ, Hong WK. Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res 20(7):1946-54, 2014. e-Pub 2013. PMID: 24366692.
- Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, Swisher SG, Simon GR, Stewart DJ, Lee JJ, Wistuba II. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res 19(23):6556-65, 2013. e-Pub 2013. PMID: 24097870.
- Kabbout M, Garcia MM, Fujimoto J, Liu DD, Woods D, Chow CW, Mendoza G, Momin AA, James BP, Solis L, Behrens C, Lee JJ, Wistuba II, Kadara H. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res 19(13):3383-95, 2013. e-Pub 2013. PMID: 23659968.
- Guo C, Shao R, Correa AM, Behrens C, Johnson FM, Raso MG, Prudkin L, Solis LM, Nunez MI, Fang B, Roth JA, Wistuba II, Swisher SG, Lin T, Pataer A. Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. J Thorac Oncol 8(3):301-8, 2013. PMID: 23370317.
- Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73(2):571-82, 2013. e-Pub 2012. PMID: 23204236.
- Chang X, Izumchenko E, Solis LM, Kim MS, Chatterjee A, Ling S, Monitto CL, Harari PM, Hidalgo M, Goodman SN, Wistuba II, Bedi A, Sidransky D. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors. PLoS One 8(7):e68966, 2013. e-Pub 2013. PMID: 23935914.
- Fujimoto J, Kadara H, Garcia MM, Kabbout M, Behrens C, Liu DD, Lee JJ, Solis LM, Kim ES, Kalhor N, Moran C, Sharafkhaneh A, Lotan R, Wistuba II. G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. J Thorac Oncol 7(12):1747-1754, 2012. PMID: 23154545.
- Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, Wistuba II, Moran CA. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer 118(11):2889-99, 2012. e-Pub 2011. PMID: 22020674.
- Long W, Foulds CE, Qin J, Liu J, Ding C, Lonard DM, Solis LM, Wistuba II, Qin J, Tsai SY, Tsai MJ, O'Malley BW. ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest 122(5):1869-80, 2012. e-Pub 2012. PMID: 22505454.
- Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee HY. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer 118(9):2454-65, 2012. e-Pub 2011. PMID: 21952750.
- Moran CA, Weissferdt A, Kalhor N, Solis LM, Behrens C, Wistuba II, Suster S. Thymomas I: a clinicopathologic correlation of 250 cases with emphasis on the World Health Organization schema. Am J Clin Pathol 137(3):444-50, 2012. PMID: 22338057.
- William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba II, Lee HY. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol 23(1):78-85, 2012. e-Pub 2011. PMID: 21430184.
- Lockwood WW, Wilson IM, Coe BP, Chari R, Pikor LA, Thu KL, Solis LM, Nunez MI, Behrens C, Yee J, English J, Murray N, Tsao MS, Minna JD, Gazdar AF, Wistuba II, MacAulay CE, Lam S, Lam WL. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One 7(5):e37775, 2012. e-Pub 2012. PMID: 22629454.
- Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, Lee JJ, Hong WK, Wistuba II. Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer 12(6):369-74, 2011. e-Pub 2011. PMID: 21729646.
- Xie Y, Xiao G, Coombes KR, Behrens C, Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, Moran C, Danenberg K, Minna JD, Wistuba II. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res 17(17):5705-14, 2011. e-Pub 2011. PMID: 21742808.
- Kim MP, Chen Y, Bekele BN, Lopez A, Khanna A, Chen JQ, Spitz MR, Behrens C, Solis L, Wismach M, Ji L, Wistuba II, Roth JA, Katz RL. Activating enhancer-binding protein-2β nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. Ann Thorac Surg 92(3):1044-50, 2011. PMID: 21871297.
- Aguayo F, Khan N, Koriyama C, González C, Ampuero S, Padilla O, Solís L, Eizuru Y, Corvalán A, Akiba S. Human papillomavirus and Epstein-Barr virus infections in breast cancer from chile. Infect Agent Cancer 6(1):7, 2011. e-Pub 2011. PMID: 21699721.
- Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna JD, Lee JJ, Kim E, Hong WK, Wistuba II, Lotan R. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res 17(6):1490-501, 2011. e-Pub 2010. PMID: 21163870.
- Singh SP, Han L, Murali R, Solis L, Roth J, Ji L, Wistuba I, Kundra V. SSTR2-based reporters for assessing gene transfer into non-small cell lung cancer: evaluation using an intrathoracic mouse model. Hum Gene Ther 22(1):55-64, 2011. e-Pub 2010. PMID: 20653396.
- Pataer A, Raso MG, Correa AM, Behrens C, Tsuta K, Solis L, Fang B, Roth JA, Wistuba II, Swisher SG. Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res 16(22):5522-8, 2010. e-Pub 2010. PMID: 20930042.
- Ooi AT, Mah V, Nickerson DW, Gilbert JL, Ha VL, Hegab AE, Horvath S, Alavi M, Maresh EL, Chia D, Gower AC, Lenburg ME, Spira A, Solis LM, Wistuba II, Walser TC, Wallace WD, Dubinett SM, Goodglick L, Gomperts BN. Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res 70(16):6639-48, 2010. PMID: 20710044.
- Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ, Wistuba II. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16(14):3743-53, 2010. e-Pub 2010. PMID: 20534738.
- Spivey KA, Banyard J, Solis LM, Wistuba II, Barletta JA, Gandhi L, Feldman HA, Rodig SJ, Chirieac LR, Zetter BR. Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev 19(5):1362-72, 2010. PMID: 20447926.
- Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 5(2):e9112, 2010. e-Pub 2010. PMID: 20161759.
- Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, Dong W, Bekele BN, Wistuba I, Johnson FM. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila) 2(12):1039-49, 2009. e-Pub 2009. PMID: 19934338.
- Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) 2(8):702-11, 2009. e-Pub 2009. PMID: 19638491.
- Tapia T, Smalley SV, Kohen P, Muñoz A, Solis LM, Corvalan A, Faundez P, Devoto L, Camus M, Alvarez M, Carvallo P. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics 3(3):157-63, 2008. e-Pub 2008. PMID: 18567944.
Invited Articles
- Hernandez S, Serrano AG, Solis Soto LM. The Role of Nerve Fibers in the Tumor Immune Microenvironment of Solid Tumors. Adv Biol (Weinh) 6(9):e2200046, 2022. e-Pub 2022. PMID: 35751462.
- Rojas F, Parra ER, Wistuba II, Haymaker C, Solis Soto LM. Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors. Cancers (Basel) 14(11), 2022. e-Pub 2022. PMID: 35681755.
Other Articles
- Han G, Sinjab A, Rahal Z, Lynch AM, Treekitkarnmongkol W, Liu Y, Serrano AG, Feng J, Liang K, Khan K, Lu W, Hernandez SD, Liu Y, Cao X, Dai E, Pei G, Hu J, Abaya C, Gomez-Bolanos LI, Peng F, Chen M, Parra ER, Cascone T, Sepesi B, Moghaddam SJ, Scheet P, Negrao MV, Heymach JV, Li M, Dubinett SM, Stevenson CS, Spira AE, Fujimoto J, Solis LM, Wistuba II, Chen J, Wang L, Kadara H Author Correction: An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature 628(8006):E1, 2024. PMID: 38499683.
- Ghosh A, Marques-Piubelli ML, Wang X, Sheu TG, Cheng J, Khan K, Lu W, Manning J, Tang G, Solis LM, Vega F CD2-negative lymphoma-associated T-cells: a potential mechanism of immune-evasion in diffuse large B-cell lymphoma. Virchows Arch 481(4):659-663, 2022. PMID: 35622145.
- Hernandez S, Lazcano R, Serrano A, Powell S, Kostousov L, Mehta J, Khan K, Lu W, Solis LM Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx® Digital Spatial Profiler. Front Oncol 12:890410, 2022. PMID: 35847846.
- Parra ER, Jiang M, Solis L, Mino B, Laberiano C, Hernandez S, Gite S, Verma A, Tetzlaff M, Haymaker C, Tamegnon A, Rodriguez-Canales J, Hoyd C, Bernachez C, Wistuba I Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies. Cancers (Basel) 12(2), 2020. PMID: 31972974.
- Barua S, Solis L, Parra ER, Uraoka N, Jiang M, Wang H, Rodriguez-Canales J, Wistuba I, Maitra A, Sen S, Rao A A Functional Spatial Analysis Platform for Discovery of Immunological Interactions Predictive of Low-Grade to High-Grade Transition of Pancreatic Intraductal Papillary Mucinous Neoplasms. Cancer Inform 17:1176935118782880, 2018. PMID: 30013304.
- Solis LM, Raso MG, Kalhor N, Behrens C, Wistuba II, Moran CA Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol 133(1):133-40, 2010. PMID: 20023269.
Abstracts
- Laberiano C, Wani K, Ingram D, Lu W, Lazcano R, Wang W, Chen Y, Biswas S, Williams D, McAlpine C, Lazar AJ, Solis Soto LM. Identifying New Therapeutic Indications for Afamitresgene Autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in Adult and Pediatric Sarcomas Using MAGE-A4 Immunohistochemistry. AACR Special Conference on Sarcomas, 2022. PMID: None.
- Nilsson MB, Yang Y, Patel S, Heeke S, Le X, Aruguman T, Robichaux J, Yu X, Poteete A, Ren X, Diao L, Shen L, Wang Q, Zhang F, Clemente LC, Soto LS, Shi C, Tran H, Bock J, Wang J, Wistuba II, Minna JD, Heymach JV. CD70 is a novel therapeutic target for EGFR mutant NSCLC with acquired, EMT-associated EGFR TKI resistance. 2022 AACR Annual Meeting, 2022. PMID: None.
- Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Yoshimura K, Behrens C, Pataer A, Parra-Cuentas E, Haymaker C, Fujimoto J, Swisher S, Heymach J, Gibbons DL, J Jack Lee J, Sepesi B, Cascone T, Solis LM, Provencio M, Wistuba II, Kadara H. Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC. 2022 AACR Annual Meeting, 2022. PMID: None.
- Sinjab A, Han G, Treekitkarnmongkol W, Hao D, Dai E, Solis LM, Moghaddam SJ, Fujimoto J, Chen J, Edwards M, Stevenson CS, Spira AE, Wang L, Kadara H. An emerging role for inflammation-associated alveolar intermediate cells in early phenotypic development of KRAS-mutant lung adenocarcinoma. 2022 AACR Annual Meeting, 2022. PMID: None.
- Han G, Sinjab A, Hao D, Bolanos LG, Dai E, Solis LM, Parra E, Swisher S, Cascone T, Sepesi B, Fujimoto J, Dubinett S, Wistuba I, Stevenson C, Spira A, Kadara H, Wang L. Immune suppressive phenotypes and pre-existing bystander T cell repertoire in early-stage lung adenocarcinoma revealed by integrative single-cell profiling. 2022 AACR Annual Meeting, 2022. PMID: None.
- Hao D, Han G, Sinjab A, Bolanos LG, Segura RL, Dai E, Solis Soto LM, Parra E, Wargo J, Swisher S, Cascone T, Sepesi B, Fujimoto J, Dubinett S, Wistuba I, Stevenson C, Spira A, Kadara H, Wang L. . Immunogenomic landscape of tumor-infiltrating B and plasma cells in early-stage lung adenocarcinoma. 2022 AACR Annual Meeting, 2022. PMID: None.
- Lima CF, Rocha PS, Fujimoto J, Stewart A, Cardnell R, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Gay CM, Kalhor N, Byers LA, Solis-Soto LM. Delta-like ligand 3 immunohistochemical expression landscape in high-grade lung neuroendocrine tumors. 2022 AACR Annual Meeting, 2022. PMID: None.
- Cascone T, William Jr WN, Weissferdt A, Leung CH, Lin HY, Pataer A, B Godoy MC, Carter BW, Federico L, Reuben A, Wadud Khan MA, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Jr GB, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, J Jack Lee J, Gibbons 1 DL, Vaporciyan AA, Heymach JV, Sepesi AB. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med, 2021. PMID: None.
- Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan Y, Lee W, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong K, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol, 2020. PMID: None.
- Lopes Carapeto FC, Solis Soto LM, Foo WC, Lu W, Vinuela Fawaz EA, Villaseca MA, Vega Pizarro EA, Araya JC, Wistuba II, Milind J, Shubham P, Kwong L. Immunological and mutational landscape of gallbladder adenocarcinoma. 2020 AACR Annual Meeting, 2020. PMID: None.
- Soundararajan R, Hollander PD, Shepherd P, Navone N, Lorenzini D, Laberiano-Fernandez C, Lu W, Zhou J, Liu J, Zhang J, Solis-Soto LM, Mani SA, Aparicio A. Modulating plasticity in aggressive variant prostate cancers. 2020 AACR Annual Meeting, 2020. PMID: None.
- Uribe LR, Wu W, Gelincik O, Bommi PV, Francisco-Cruz A, Solis LM, Lynch PM, Lim R, Stoffel E, Kanth P, N Jewel Samadder N, Mork ME, Taggart MW, Milne GL, Marnett LJ, Vornik L, Liu DD, Revuelta M, Chang K, Y Nancy You Y, Kopelovich L, Wistuba II, J Jack Lee J, Sei S, Shoemaker RH, Szabo E, Richmond E, Umar A, Perloff M, Brown PH, Lipkin SM, Vilar E. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. 2020 AACR Annual Meeting, 2020. PMID: None.
- Lazcano Segura RN, Catao A, Solis LM, Jiang M, Tamegnon A, Fujimoto J, Rodriguez-Canales J, Chow CB, Behrens C, Kalhor N, Weissferdt A, Heymach J, Swisher S, Sepesi B, Lee J, Moran C, Futreal A, Zhang J, Parra ER, Wistuba II, Tetzlaff MT, Francisco-Cruz A. Tertiary lymphoid structures features associate with outcome in non-small cell lung carcinoma. 2020 AACR Annual Meeting, 2020. PMID: None.
- N Barreto CM, Solis-Soto LM, Salazar R, Gite S, Parra ER, Mino B, Ingram D, Wani KM, Leung CH, Lin H, Wistuba II, Lazar A, Wang W. Characterization of immune cell biomarkers in undifferentiated pleomorphic sarcoma. 2020 AACR Annual Meeting, 2020. PMID: None.
- Rocha P, Solis L, Parra E, Shi O, Mino B, Sinha VC, Rinkenbaugh A, Tamegnon A, Duncan M, Lu W, Jiang M, Kakarala L, Burks JK, Piwnica-Worms H, Haymacker C, Teztlaff M, Wistuba I, Francisco-Cruz A. Immuno-oncology panel optimization for imaging mass cytometry and digital image analysis of tumor tissues. 2020 AACR Annual Meeting, 2020. PMID: None.
- Noia Barreto CM, Ledesma DA, Gite S, Solis LM, Jiang M, Pandurengan RK, Wolff R, Javle M, Pant S, Varadhachary G, Shroff RT, Vainstein-Haras A, Sorani E, Lustig TM, Kashtan O, Gozlan Y, Townson SM, Fahey JM, Yao J, Wistuba II, Overman M, Fogelman D, Parra ER. High cytotoxic T-cell or polymorphonuclear cell infiltrates in the tumor microenvironment correlate with responses to BL8040 plus pembrolizumab combination therapy in metastatic pancreatic tumors: Scientific correlates of a phase II clinical trial. 2020 AACR Annual Meeting, 2020. PMID: None.
- Sun X, Parra E, Jiang M, Solis L, Sahin A, Jennifer Litton IW, Yang F. Characterizing PD-L1 Expressing Immune Cells in Triple Negative Breast Cancer by Multiplex Immunofluorescence. 2020 USCAP Annual Meeting, 2020. PMID: None.
- Marques-Piubelli M, Segura RL, Ledesma D, Barreto1 CN, Weber P, Bravo E, Villaseca M, Wistuba I, Araya J, Soto LS. Immune Infiltrates Associated with Tumor Budding in Gastric Adenocarcinoma: A Histopathological Characterization. 2020 USCAP Annual Meeting, 2020. PMID: None.
- Ferrufino-Schmidt M1, Duenas D, Parra E, Soto LS, Zhang J, Clemens M, L Jeffrey Medeiros L, Sanchez-Espiridion3 B, Chakraborty M, Marques-Piubelli M, J Jack Lee J, Wistuba I, Miranda R. PD-L1 and CD8 Expression Correlate with Aggressive Behavior of Breast Implant Anaplastic Large Cell Lymphoma Cells. 2020 USCAP Annual Meeting, 2020. PMID: None.
- Strati P, Schlette E, Soto LS, Duenas D, Jan Burger IWA. Characterization of bone marrow tumor associated macrophages in patients with chronic lymphocytic leukemia treated with Ibrutinib, 2019 AACR Annual Meeting. Cancer Res, 2019. PMID: None.
- Tong Z, Mejia A, Veeranki O, Verma A, Correa A, Patel V, Dokey R, Solis L, Mino B, Kathkuda R, Canales J, Lin S, Krishnan S, Kopetz S, Blum M, Ajani J, M Maru WHAD. Targeting CDK9 and MCL-1 by a New CDK9/p-TEFB Inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma, 2019 AACR Annual Meeting. Cancer Res, 2019. PMID: None.
- Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis LM, Dejima H, Cuentas ER, Mino B, Abraham R, Ikeda N, Luthra R, Lee JJ, Kadara H, I Wistuba JTHAI. Characterization of the immune microenvironment in brain metastasis from non-small cell lung cancer, 2019 AACR Annual Meeting. Cancer Res, 2019. PMID: None.
- Francisco-Cruz A, Uraoka N, Liu S, Parra ER, Solis LM, Mino B, Dasari A, Rodriguez-Canales J, Overman MJ, Loree JM, Yao JC, Wistuba II, S Estrella DMHAJ. Study of the immune contexture in advanced pancreatic neuroendocrine tumors reveals tumor-associated macrophages as promoters of poor survival, 2019 AACR Annual Meeting. Cancer Res, 2019. PMID: None.
- Treekitkarnmongkol W, Solis LM, Kai K, Sasai K, Wistuba II, Sahin AA, Wong KK, Thompson AM, Jltsumori Y, Lee JM, Qin L, Bawa-Khalfe T, Rad R, Abbott CM, Subrata Sen HKA. Aurora-A is elevated in cancer cells due to inactivation of EF1A2-PTEN-GSK3b regulated late S-G2 phase specific degradation pathway, 2019 AACR Annual Meeting. Cancer Res, 2019. PMID: None.
- Salazar R, Solis L, Behrens C, Solorzano JL, Zhang J, Mino B, Parra-Cuentas E, Zhang J, Vaporciyan A, Rice DC, Kalhor N, Moran C, Gibbons DL, Weissferdt A, Sepesi B, Ignacio Wistuba MD. CD73 Immunohistochemical Expression in Malignant Cells and Correlation with Immune Infiltrate in Non-Small Cell Lung Carcinoma (NSCLC), IASLC 19th World Conference on Lung Cancer. None, 2018. PMID: None.
- Solis LM, Uraoka N, Parra ER, Shen Y, Wei W, Jiang M, Mino B, Affolter K, Scaife CL, Yip-Schneider M, C Max Schmidt C, Firpo M, Mulvihill SJ, Koay EJ, Wang H, Wistuba II, Maitra A, Sen S. Characterization of immune profiling of pancreatic intraductal papillary mucinous neoplasm (IPMN) using multiplex immunofluorescence and image analysis approaches. None, 2018. PMID: None.
- Senra J, Howe K, Villalobos P, Mino B, Solis L, Behrens C, Gao Q, Sanderson JP, Saini M, Higgins C, Gouveia C, Debnam P, Chagin K, Amado R, Gerry AB, Pumphrey NJ, Maroto M, Sepesi B, Hwu P, Hong D, Mittendorf EA, Blumenschein G, Wistuba II, Binder-Scholl G. Affinity-enhanced T Cell Receptor (TCR) for Adoptive T Cell Therapy targeting MAGE-A4. None, 2018. PMID: None.
- Solis LM, Foo WC, Mino B, Parra E, I Wistuba RAI, Kwong L, Javle M, Shroff R. Tumor-Associated Inflammatory Cells And Immune-Checkpoints markers Correlates With Clinicopathological Characteristics In Intrahepatic Cholangiocarcinoma (ICC). None, 2018. PMID: None.
- Solis L, Llanos D. Case Report. immature teratoma of the orbit. Santa Bárbara Hospital. Sucre- Bolivia. None, 2013. PMID: None.
- Quintas-Cardama A, Post SM, Solis L, Xiong S, Wistuba II, Lozano G. DEAR1, a novel tumor suppressor, negative regulator of epithelial-mesenchymal transition, and prognostic factor in non-small cell lung cancer. None, 2012. PMID: None.
- Zhang W, Yao Y, Yan J, Zhang Y, Rios J, Girard L, Pertsemlidis A, Wakeland W, Xie Y, Solis LM, Wistuba II, Hanash SM, Minna JD, Gazdar AF. BRG1 (SMARCA4) protein loss has profound effects on the transcriptome of non-small cell lung cancer (NSCLC) cell lines. None, 2012. PMID: None.
- Galindo H, Solis L, Fujimoto J, Hanson NE, McDowell C, Riquelme E, Tang X, Behrens C, Lee JJ, Kim ES, Wistuba II, Erickson HS. Formalin-fixed and paraffin-embedded (FFPE) DNA recovery for high-throughput genotyping of lung cancer tissues. None, 2012. PMID: None.
- Behrens C, Solis L, Lin H, Tang X, Yuan P, Kadara H, Riquelme E, Galindp H, Hong WK, Lee J, Wistuba II. Analysis of EZH2 and TTF-1 protein expression identifies a subset of lung adenocarcinomas with better prognosis. None, 2012. PMID: None.
- Kabbout M, Garcia MM, Fujimoto J, Chow C, Woods D, Koch P, Momin A, James BP, Solis LM, Behrens C, Wistuba II, Kadara H. Tumor suppressor effects of ETS2 transcriptional factor in human non-small cell lung cancer. None, 2012. PMID: None.
- Galindo H, Solis L, Hanson NE, Junya Fujimoto CM, Riquelme E, Tang X, Behrens C, J Jack Lee J, Kim ES, Wistuba II, Erickson HS. High-throughput Mutation Analysis of Formalin Fixed Paraffin-Embedded (FFPE) Non-small Cell Lung Cancer Tissues. None, 2012. PMID: None.
- Kim J, Kim ES, Liu D, J Jack Lee J, Solis L, Behrens C, Lippman S, Hong WK, Wistuba II, Lee H. Insulin receptor expression and survival of patients with non-small cell lung cancer. None, 2011. PMID: None.
- Solis LM, Raso MG, Fujimoto J, Behrens C, Woods DM, Mendoza G, Kalhor N, Moran CA, Wistuba II. Molecular abnormalities associated to the progression of lung adenocarcinomas with BAC features from non-invasive to invasive patterns. None, 2011. PMID: None.
- Behrens C, Yuan P, Solis L, Saintigny P, Kadara H, Fujimoto J, Moran C, Swisher SG, Heymach JV, Wistuba II. EZH2 expression is an early event in the pathogenesis of non-small cell lung cancer (NSCLC) and correlates with tumor progression. None, 2011. PMID: None.
- Saintigny P, Liu D, J Jack Lee J, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Hong WK, Kurie JM, Wistuba II, Koo JS. CXCR2 expression in tumor cells is associated with an adverse outcome in a large set of non-small-cell lung cancer (NSCLC). None, 2011. PMID: None.
- Fujimoto J, Kadara H, Behrens C, Liu D, J Jack Lee J, Solis LM, Kim E, Sharafkhaneh A, Wistuba II, Reuben L. Implication of GPRC5A loss in lung carcinogenesis in patients with and without chronic obstructive pulmonary disease. None, 2011. PMID: None.
- J S Kim J, E S Kim E, D Liu D, J J Lee J, L Solis L, P Yuan P, C Behrens C, W K Hong W, I I Wistuba I, H Y Lee H. Comprehensive analysis of expression patterns of insulin-like growth factor and Src pathway in patients with non-small cell lung cancer: Two large, independent series of tissue microarray. None, 2010. PMID: None.
- K A Gold K, E S Kim E, J J Lee J, C Behrens C, L Solis L, D Liu D, P Yuan P, B D Casey B, I I Wistuba I, W K Hong W. Biologic risk model development for recurrent and second primary tumors (SPTs) in patients (pts) with early stage non-small cell lung cancer (ES NSCLC). None, 2010. PMID: None.
- Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II. Sex determining region Y-box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. None, 2010. PMID: None.
- Behrens C, Lin H, Nunez M, Yuan P, Solis L, Raso MG, Prudkin L, Sun M, Li X, Tang X, Roth JA, Minna JD, Stewart DJ, Hong WK, J Jack Lee J, Wistuba II. Differences in protein expression patterns in lung adenocarcinomas arising in never versus ever smokers. None, 2010. PMID: None.
- Zenali MJ, Solis LM, Raso MG, Kalhor N, Wistuba II, Moran CA. Mucinous Adenocarcinoma (Colloid Carcinoma) of the Lung, an Immunohistochemical and Molecular Analysis. None, 2010. PMID: None.
- Solis LM, Behrens C, Bekele BN, Suraokar M, Ozburn N, Moran CA, Minna J, Stewart D, Swisher S, Corvalan AH, Wistuba I. Keap1 and Nrf2 expression in non-small cell lung carcinomas correlates with clinico-pathological features. None, 2009. PMID: None.
- LM Solis LM, MG Raso MG, C Behrens C, I Wistuba and CA Moran I. Primary Oncocytic Adenocarcinoma of the Lung: Clinicopathological and Immunohistochemical Study of 16 Cases. None, 2009. PMID: None.
- Solis LM, Behrens C, Bekele BN, Suraokar M, Ozburn N, Moran CA, Minna J, Stewart D, Swisher S, Corvalan AH, Wistuba I. Keap1 and Nrf2 expression in non-small cell lung carcinomas correlates with clinico-pathological features. None, 2009. PMID: None.
- C Alvarez C, T Tapia T, L Solis L, A Corvalan A, M Alvarez M, Rozemblun E, Munroe D, P Carvallo P. Genomic Profile of BRCA1 ans BRCA2 Tumor Biopsies from chilean Patients with Hereditary Breast Cancer: An Array-CGH approach. 99th Annual Meeting American Association for Cancer Research. None, 2008. PMID: None.
- M Vallejos M, C Alvarez C, L Solís L, A Corvalan A, D Munroe D, P Carballo P. Genes participating in the development of ovary cancer with a BRCA 2 mutations: array-CGH analysis. None, 2006. PMID: None.
- C Alvarez C, E Rozenblum E, L Solís L, A Corvalan A, D Munroe D, P Carballo P. Genomic deletions and amplifications in hereditary breast cancer: a CGH array analysis. None, 2006. PMID: None.
- T Tapia T, S Samelley S, L Solís L, P Faundez P, A Corvalan A, P Carvallo P. Promoter methylation status of BRCA1 and ATM in hereditary breast cancer tumors. None, 2006. PMID: None.
- L Solis L, S Magedson S, A Corvalan A. cerb-b2 oncogen amplification by fluorescence in situ hybridization in breast cancer specimens. None, 2006. PMID: None.
- L Solis L, D Oddó D, P Cabello P, M Carmona M, M Camus M, A Leon A, R Claure R, F Ossandon F. Immunohistochemical p16 expression in sentinel nodes with metastatic breast carcinoma. None, 2006. PMID: None.
- L Solis L. Histological features of BRCA1 negative hereditary breast carcinomas. None, 2005. PMID: None.
- L Solis L. Methylation profile of tumor suppresor genes in breast carcinoma. None, 2005. PMID: None.
- C Risueño C, L Solis L, J Gutierrez J, A Corvalan A. Down-regulation of bbc3, flt1 and gstm3 is associated with lymph node metastases in Breast Carcinoma. None, 2005. PMID: None.
- L Solis L. A century of advances between the synapses and the memory. None, 2001. PMID: None.
- L Solis L. Case report: Tumors of Posterior fossa. Hospital De Lajastambo, Sucre-Bolivia. None, 2001. PMID: None.
- L Solis L. Parasitological examination of the umbilical cord blood for Trypanozoma Cruzi’s detection. Obstetrics and Gynecology’ Hospital. Sucre- Bolivia. None, 2001. PMID: None.
Book Chapters
- Soto S, LM, Wang, H. Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. In: Handbook of Cancer and Immunology. None. Springer, 2022.
- Solis LM, Wistuba II. Diagnostic Pathology of Peluropulmonary Neoplasia. In: Molecular Pathology of Lung Cancer. In: None. None. None, None, 2012.
Grant & Contract Support
Title: | Center for Gastric Pre-Cancer Atlas of Multidimensional Evolution in 3D (GAME3D) |
Funding Source: | NIH |
Role: | Co-I |
Title: | Molecular and Immunological Heterogeneity of Small Cell Lung Cancer (SCLC) and Its Impact on Relapse and Therapeutic Response |
Funding Source: | NIH |
Role: | Co-I |
Title: | Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC) |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Development of miR-27a* for the Treatment of Head and Neck Squamous Cell Carcinoma |
Funding Source: | NIH/NIDCR |
Role: | Co-I |
Title: | MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMAC |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Dissecting and Targeting Tumor-TME Crosstalk to Forestall Acquired KRASG12C Inhibitor Resistance in NSCLC |
Funding Source: | NIH |
Role: | Co-I |
Title: | Targeting STAT3 to Prevent Non-Small Cell Lung Cancer (NSCLC) in Patients with Chronic Obstructive Pulmonary Disease (COPD) |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Evolution of Individual Patient’s Tumor Immune Microenvironment in the Development of Clear Cell Renal Cell Carcinoma |
Funding Source: | Department of Defense (DOD) |
Role: | Co-I |
Title: | Dissecting and Targeting Mechanisms of Genomic Instability-Triggered Immune Evasion in RBM10-Deficient Non-Small Cell Lung Cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Molecular Dissecting and Targeting YAP1 Mediated Cancer Stemness and Immune Suppression in Advanced Gastric Adenocarcinoma |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | Therapeutic approaches for TGF-beta-enriched minimal residual disease in patients with colorectal cancer |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-I |
Title: | Understanding and Harnessing Immune-Modulatory Effects of Covalent KRASG12C Inhibitors in KRASG12C-Mutant Non-Small Cell Lung Cancer |
Funding Source: | NIH/NCI |
Role: | Co-I |
Title: | SIV: STRATEGIC Alliance Agreement |
Funding Source: | Allogene Therapeutics |
Role: | Collaborator |
Title: | SIV Merck Master Agreement for $12.5 Million for Clinical Trial |
Funding Source: | Merck |
Role: | Collaborator |
Title: | SIV EMD Serono Strategic Collaboration Agreement |
Funding Source: | EMD SERONO INC |
Role: | Co-I |
Title: | SIV Alliance- Strategic Collaboration Agreement |
Funding Source: | Adaptimmune |
Role: | Collaborator |
Title: | SIV Alliance- Strategic Collaboration Agreement |
Funding Source: | Adaptimmune |
Role: | Co-I |
Title: | SIV Alliance- Strategic Collaboration Agreement |
Funding Source: | Adaptimmune |
Role: | Co-I |
Title: | Unleashing NLRC-5: Harnessing Anti-Tumor Immunity for Cancer Therapy |
Funding Source: | Cancer Prevention and Research Institute of Texas |
Role: | Co-I |
Title: | KRAS Inhibitor-Induced Adaptive Resistance Mechanisms and Immune Suppression in NSCLC |
Funding Source: | Cancer Prevention and Research Institute of Texas |
Role: | Co-I |
Title: | Advancing Antibody Drug Conjugates in Penile Cancer: Preclinical Modeling and Clinical Correlation of Target Expression |
Funding Source: | CPRIT |
Role: | Co-I |
Title: | Understanding the Allele Specific Mechanisms of Response and Resistance to KRAS Inhibitors in Pancreatic Cancer |
Funding Source: | Cancer Prevention and Research Institute of Texas |
Role: | Co-I |
Title: | KRAS Inhibitor-Induced Adaptive Resistance Mechanisms and Immune Suppression in NSCLC |
Funding Source: | NIH |
Role: | Co-I |
Title: | Deep Attention and Learning of Glioblastomas Spatial Tumor Immune Microenvironment |
Funding Source: | NIH |
Role: | Co-I |
Title: | Targeting Adaptive Mutability as a Novel Therapeutic Approach in BRAF Mutant Colorectal Cancer |
Funding Source: | The University of Texas MD Anderson Cancer Center IRG Program |
Role: | Co-I |
Title: | Spatial Evolution of Immune Cell Dysfunction during Development of Oligometastatic RCC and its Perturbation by Radiation Therapy |
Funding Source: | National Comprehensive Cancer Network (NCCN) |
Role: | Co-I |
Title: | Assessment of B Cell Spatial Distribution in Non-Small Cell Lung Cancer and its Impact in the Tumor Microenvironment Using High-Plex Digital Spatial Profiling |
Funding Source: | The University of Texas MD Anderson Cancer Center – Division of Pathology and Laboratory Medicine |
Role: | PI |
Title: | CD70 Expression in T cell lymphomas |
Funding Source: | CRISPR Therapeutics AG |
Role: | Co-PI |
Title: | Evaluation of Pre- and Post-Treatment Biopsy Tissue from SCLC Patients Treated with the Aurora Kinase B Inhibitor AZD2811-NP |
Funding Source: | AstraZeneca |
Role: | Co-I |
Title: | Elucidating aberrant splicing-induced immune pathway activation in RBM10-deficient KRAS-mutant NSCLC and harnessing its potential for precision immunotherapy |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | CO-I |
Title: | STRATEGIC ALLIANCE Agreement-4D Pharma PLC |
Funding Source: | 4D Pharma PLC |
Role: | Co-I |
Title: | STRATEGIC ALLIANCE Agreement-Amgen |
Funding Source: | Amgen Inc |
Role: | Collaborator |
Title: | SIV Division of Cancer Medicine Genentech SIV Alliance |
Funding Source: | Genentech Alliance |
Role: | Co-I |
Title: | SIV Merck Master Agreement for $12.5 Million for Clinical Trial |
Funding Source: | Merck |
Role: | Co-I |
Title: | Dissecting Sex-Specific Immunomodulatory Mechanisms and Phenotypes That Impact Lung Adenocarcinoma Development and Therapy |
Funding Source: | NIH/NCI |
Role: | CO-I |
Title: | Defining the Roles of Tumor-Infiltrating B Cells in Early Development and Immunotherapy of Lung Cancer |
Funding Source: | NIH Research project Grant |
Role: | CO-I |
Title: | Profiling the Peritoneal Environment of Patients with Gastric Cancer Metastatic to the Peritoneum |
Funding Source: | DeGregorio Foundation |
Role: | CO-I |
Title: | Targeting CD73 in Select Sarcomas |
Funding Source: | American Cancer Society (ACS) |
Role: | Collaborator |
Title: | Improving Response to Immunotherapy in Patients with Lung Cancer and Chronic Hepatitis C Virus Infection after Direct-Acting Antiviral Therapy |
Funding Source: | NIH/NCI |
Role: | CO-I |
Title: | Defining the Influence of Tumor Thickness on Unique Immune Signatures in Malignant Pleural Mesothelioma |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
Title: | MD Anderson Sarcoma SPORE |
Funding Source: | NIH/NCI |
Role: | Collaborator |
Title: | Metabolic Imaging and Inhibition in Castration Resistant Prostate Cancer |
Funding Source: | Department of Defense (DOD) |
Role: | CO-I |
Title: | Regulation of lung cancer metastasis by cancer-associated fibroblasts |
Funding Source: | NIH Research Project Grant |
Role: | Sr. Research scientist |
Title: | Novel therapeutic strategies for SMARCA4/BRG1-deficient lung adenocarcinoma |
Funding Source: | University of Southwestern Medical Center Dallas |
Role: | PI |
Title: | BC171925: EF1A2-SCF Complex Regulated Ubiquitination Pathway as Predictor of Prognosis and Drug Response in Breast Cancer |
Funding Source: | Department of Defense (DOD) |
Role: | CO-I |
Patient Reviews
CV information above last modified December 09, 2024